Sickle cell disease: progress towards combination drug therapy.

Area of Science:

• Hematology
• Genetics
• Pharmacology

Background:

• Sickle cell anaemia (SCA) was first described in 1910, with the genetic basis elucidated decades later.
• The establishment of Comprehensive Sickle Cell Centers marked a milestone in understanding and treating sickle cell disease (SCD).
• Hydroxycarbamide, approved in 1998, showed efficacy but faced limited clinical acceptance, driving the search for new agents.

Purpose of the Study:

• To review the progress in drug development for sickle cell disease (SCD).
• To discuss the potential of combination drug therapy for SCD.
• To highlight advancements in curative treatments like stem cell transplant and gene therapy.

Main Methods:

• Review of historical milestones in SCA/SCD research and treatment.
• Analysis of drug development pathways targeting SCD pathophysiology.
• Examination of ongoing clinical trials for novel SCD therapies.

Main Results:

• Three new drugs have been FDA-approved for SCA since 2018.
• Over 30 treatment intervention trials are currently investigating complementary mechanisms.
• Significant progress has been made in developing both disease-modifying and curative therapies.

Conclusions:

• The field is entering an era of effective and safe combination drug therapy for SCD.
• Hematopoietic stem cell transplant and gene therapy offer potential curative options.
• Continued research is crucial for optimizing SCD treatment strategies.